<p>Avalo Therapeutics, Inc.（纳斯达克代码：AVTX - 免费报告）- HC Wainwright 的股票研究分析师在 5 月 14 日星期四向投资者发布的报告中上调了 Avalo Therapeutics 2026 年第二季度每股收益（EPS）预期。HC Wainwright 分析师 M. Kapoor 现在预计该公司本季度每股收益为（$0.59），高于之前预测的（$1.04）。HC Wainwright 对该股票给予 “买入” 评级，目标价为 $35.00。Avalo Therapeutics 当前全年的共识收益预期为每股（$3.00）。HC Wainwright 还对 Avalo Therapeutics 2026 年第三季度的收益预期为每股（$0.37），2026 年第四季度的收益预期为每股（$0.39），2026 财年的收益预期为每股（$2.02），2027 年第一季度的收益预期为每股（$0.39），2027 年第二季度的收益预期为每股（$0.43），2027 年第三季度的收益预期为每股（$0.45），2027 年第四季度的收益预期为每股（$0.50），以及 2027 财年的收益预期为每股（$1.78）。</p>
<p>获取 <strong>Avalo Therapeutics</strong> 警报：</p>
<p>Avalo Therapeutics（纳斯达克代码：AVTX - 获取免费报告）最近在 5 月 13 日星期三发布了季度收益结果。该公司报告本季度每股收益为（$0.98），超出共识预期的（$1.00）$0.02。</p>
<p>其他几位股票研究分析师也对该公司发表了看法。Weiss Ratings 在 4 月 8 日星期三的研究报告中重申了对 Avalo Therapeutics 股票的 “卖出（d-）” 评级。Piper Sandler 在 5 月 11 日星期一的研究报告中重申了 “增持” 评级，并将 Avalo Therapeutics 股票的目标价从 $48.00 上调至 $60.00。Mizuho 在 5 月 14 日星期四的研究报告中将 Avalo Therapeutics 的目标价从 $39.00 上调至 $45.00，并给予该公司 “跑赢大盘” 的评级。Wolfe Research 在 4 月 9 日星期四开始对 Avalo Therapeutics 进行覆盖。他们对该股票给予 “跑赢大盘” 的评级，并设定目标价为 $48.00。最后，Citizens Jmp 在 5 月 14 日星期四的研究报告中将 Avalo Therapeutics 的目标价从 $62.00 下调至 $55.00，并对该股票设定了 “市场跑赢大盘” 的评级。共有 11 位股票研究分析师对该股票给予了买入评级，1 位分析师对该公司的股票给予了卖出评级。根据 MarketBeat，该股票的共识评级为 “适度买入”，共识目标价为 $48.13。</p>
<p><strong>查看我们对 Avalo Therapeutics 的最新分析</strong></p>
<h2>Avalo Therapeutics 股价下跌 8.9%</h2>
<p>AVTX 股票在星期二开盘价为 $16.16。Avalo Therapeutics 的 1 年最低价为 $3.43，1 年最高价为 $24.27。该公司的市值为 $4.7391 亿，市盈率为 -2.96，贝塔系数为 0.78。该公司的 50 日移动平均线为 $15.80，200 日移动平均线为 $16.43。</p>
<h2>机构投资者对 Avalo Therapeutics 的看法</h2>
<p>大型投资者最近买入和卖出了该公司的股票。BIT Capital GmbH 在第三季度购买了 Avalo Therapeutics 的新股份，价值约 $25,000。PFS Partners LLC 在第四季度将其在 Avalo Therapeutics 的持仓增加了 100.0%。PFS Partners LLC 现在拥有该公司 2,000 股股票，价值 $36,000，此前在上个季度又购买了 1,000 股。Dimensional Fund Advisors LP 在第三季度购买了 Avalo Therapeutics 的新股份，价值约 $143,000。Boothbay Fund Management LLC 在第二季度购买了 Avalo Therapeutics 的新股份，价值约 $56,000。最后，AlphaCentric Advisors LLC 在第一季度购买了 Avalo Therapeutics 的新股份，价值约 $174,000。目前 87.06% 的股票由机构投资者持有。</p>
<h2>内部人员买卖</h2>
<p>在相关消息中，内部人士 Paul Varki 于 5 月 6 日星期三出售了 75,063 股该股票。该股票的平均售价为 $20.17，总交易额为 $1,514,020.71。出售后，内部人士直接持有该公司 3,634 股，价值 $73,297.78。这代表其持股比例减少了 95.38%。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，内部人士 Mittie Doyle 于 4 月 6 日星期一出售了 3,970 股该股票。该股票的平均售价为 $18.01，总价值为 $71,499.70。出售后，内部人士持有该公司 3,622 股，价值约 $65,232.22。此交易代表其持股比例减少了 52.29%。有关此交易的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在过去三个月内共出售了价值 $2,501,346 的 138,078 股公司股票。内部人士持有该公司 4.46% 的股票。</p>
<h2>Avalo Therapeutics 新闻汇总</h2>
<p>以下是本周影响 Avalo Therapeutics 的主要新闻：</p>
<ul>
<li>积极情绪：HC Wainwright 对 Avalo Therapeutics 维持买入评级，并重申 $35 的目标价，显示出对公司长期上涨潜力的信心。</li>
<li>积极情绪：该公司上调了多个时期的收益预期，包括 2026 财年每股（$2.02）和 2027 财年每股（$1.78），表明对之前预测的期望有所改善。</li>
<li>积极情绪：HC Wainwright 还显著提高了对 2026 年第四季度、第三季度和第二季度的每股收益预期，这可以被解读为对 Avalo 前景的更积极看法。</li>
<li>中性情绪：这些更新是研究报告的修订，而不是公司公告，因此可能会影响情绪，但本身并不会改变 Avalo 的基本面。AVTX 股票页面</li>
<li>消极情绪：尽管进行了升级，Avalo 仍预计在预测期内亏损，2025 财年共识收益约为每股（$3.00），突显了持续盈利的风险。</li>
</ul>
<h2>关于 Avalo Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Avalo Therapeutics 是一家临床阶段的生物技术公司，专注于发现、开发和商业化用于心脏代谢、纤维化和炎症疾病的新疗法。该公司的专有药物设计平台能够创造具有优化药代动力学特征的长效前药，旨在提高疗效、安全性和患者依从性。通过利用这一技术，Avalo 旨在解决现有治疗方法未能充分满足的疾病进展的关键驱动因素。</p>
<p>其主要项目包括 AVTX-002，这是一种首创的前药候选药物，旨在抑制肾素原，用于治疗高血压及相关心血管疾病，以及 AVTX-006，这是一种早期候选药物，针对与纤维化和代谢功能障碍相关的通路。</p>
<h2>另请参见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Avalo Therapeutics</li>
<li>为什么特朗普的亚马逊股票出售可能根本无关紧要</li>
<li>为什么应用光电子公司的股票可能接近转折点</li>
<li>从高收益到高增长：三只提升股息的股票</li>
<li>Everspin Technologies 会成为下一个 AI 边缘突破吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZUWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Avalo Therapeutics 吗？</h2>
<p>在考虑 Avalo Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Avalo Therapeutics 并不在名单上。</p>
<p>虽然 Avalo Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AVTX

纽交所高增长板生物技术指数 ETF - First Trust

IBBQ

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>HC Wainwright 分析师将 Avalo Therapeutics 2026 年第二季度每股收益预期从（$1.04）上调至（$0.59），维持 “买入” 评级，目标价为 $35.00。全年收益的共识预期为每股（$3.00）。Avalo 的股票共识评级为 “适度买入”，目标价为 $48.13。近期还注意到了一些内部人士的股票出售和机构投资</p>

<p>Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) - Equities research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of Avalo Therapeutics in a note issued to investors on Thursday, May 14th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.59) per share for the quarter, up from their previous forecast of ($1.04). HC Wainwright has a &#34;Buy&#34; rating and a $35.00 price objective on the stock. The consensus estimate for Avalo Therapeutics' current full-year earnings is ($3.00) per share. HC Wainwright also issued estimates for Avalo Therapeutics' Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($2.02) EPS, Q1 2027 earnings at ($0.39) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.45) EPS, Q4 2027 earnings at ($0.50) EPS and FY2027 earnings at ($1.78) EPS.</p>
<div class="lb-trans"><p>Avalo Therapeutics, Inc.（纳斯达克代码：AVTX - 免费报告）- HC Wainwright 的股票研究分析师在 5 月 14 日星期四向投资者发布的报告中上调了 Avalo Therapeutics 2026 年第二季度每股收益（EPS）预期。HC Wainwright 分析师 M. Kapoor 现在预计该公司本季度每股收益为（$0.59），高于之前预测的（$1.04）。HC Wainwright 对该股票给予 “买入” 评级，目标价为 $35.00。Avalo Therapeutics 当前全年的共识收益预期为每股（$3.00）。HC Wainwright 还对 Avalo Therapeutics 2026 年第三季度的收益预期为每股（$0.37），2026 年第四季度的收益预期为每股（$0.39），2026 财年的收益预期为每股（$2.02），2027 年第一季度的收益预期为每股（$0.39），2027 年第二季度的收益预期为每股（$0.43），2027 年第三季度的收益预期为每股（$0.45），2027 年第四季度的收益预期为每股（$0.50），以及 2027 财年的收益预期为每股（$1.78）。</p>
</div><p>Get <strong>Avalo Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Avalo Therapeutics</strong> 警报：</p>
</div><p>Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.02.</p>
<div class="lb-trans"><p>Avalo Therapeutics（纳斯达克代码：AVTX - 获取免费报告）最近在 5 月 13 日星期三发布了季度收益结果。该公司报告本季度每股收益为（$0.98），超出共识预期的（$1.00）$0.02。</p>
</div><p>Several other equities research analysts have also weighed in on the company. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Avalo Therapeutics in a research note on Wednesday, April 8th. Piper Sandler reiterated an &#34;overweight&#34; rating and issued a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a research note on Monday, May 11th. Mizuho upped their price objective on Avalo Therapeutics from $39.00 to $45.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday, May 14th. Wolfe Research began coverage on Avalo Therapeutics in a research note on Thursday, April 9th. They issued an &#34;outperform&#34; rating and a $48.00 price objective on the stock. Finally, Citizens Jmp lowered their price objective on Avalo Therapeutics from $62.00 to $55.00 and set a &#34;market outperform&#34; rating on the stock in a research note on Thursday, May 14th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $48.13.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也对该公司发表了看法。Weiss Ratings 在 4 月 8 日星期三的研究报告中重申了对 Avalo Therapeutics 股票的 “卖出（d-）” 评级。Piper Sandler 在 5 月 11 日星期一的研究报告中重申了 “增持” 评级，并将 Avalo Therapeutics 股票的目标价从 $48.00 上调至 $60.00。Mizuho 在 5 月 14 日星期四的研究报告中将 Avalo Therapeutics 的目标价从 $39.00 上调至 $45.00，并给予该公司 “跑赢大盘” 的评级。Wolfe Research 在 4 月 9 日星期四开始对 Avalo Therapeutics 进行覆盖。他们对该股票给予 “跑赢大盘” 的评级，并设定目标价为 $48.00。最后，Citizens Jmp 在 5 月 14 日星期四的研究报告中将 Avalo Therapeutics 的目标价从 $62.00 下调至 $55.00，并对该股票设定了 “市场跑赢大盘” 的评级。共有 11 位股票研究分析师对该股票给予了买入评级，1 位分析师对该公司的股票给予了卖出评级。根据 MarketBeat，该股票的共识评级为 “适度买入”，共识目标价为 $48.13。</p>
</div><p><strong>View Our Latest Analysis on Avalo Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Avalo Therapeutics 的最新分析</strong></p>
</div><h2>Avalo Therapeutics Trading Down 8.9%</h2>
<div class="lb-trans"><h2>Avalo Therapeutics 股价下跌 8.9%</h2>
</div><p>AVTX stock opened at $16.16 on Tuesday. Avalo Therapeutics has a 1-year low of $3.43 and a 1-year high of $24.27. The firm has a market cap of $473.91 million, a P/E ratio of -2.96 and a beta of 0.78. The business's 50 day moving average is $15.80 and its 200-day moving average is $16.43.</p>
<div class="lb-trans"><p>AVTX 股票在星期二开盘价为 $16.16。Avalo Therapeutics 的 1 年最低价为 $3.43，1 年最高价为 $24.27。该公司的市值为 $4.7391 亿，市盈率为 -2.96，贝塔系数为 0.78。该公司的 50 日移动平均线为 $15.80，200 日移动平均线为 $16.43。</p>
</div><h2>Institutional Investors Weigh In On Avalo Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Avalo Therapeutics 的看法</h2>
</div><p>Large investors have recently bought and sold shares of the business. BIT Capital GmbH bought a new stake in Avalo Therapeutics during the 3rd quarter worth approximately $25,000. PFS Partners LLC grew its position in Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company's stock worth $36,000 after acquiring an additional 1,000 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Avalo Therapeutics during the 3rd quarter worth approximately $143,000. Boothbay Fund Management LLC bought a new stake in Avalo Therapeutics during the 2nd quarter worth approximately $56,000. Finally, AlphaCentric Advisors LLC bought a new stake in Avalo Therapeutics during the 1st quarter worth approximately $174,000. 87.06% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该公司的股票。BIT Capital GmbH 在第三季度购买了 Avalo Therapeutics 的新股份，价值约 $25,000。PFS Partners LLC 在第四季度将其在 Avalo Therapeutics 的持仓增加了 100.0%。PFS Partners LLC 现在拥有该公司 2,000 股股票，价值 $36,000，此前在上个季度又购买了 1,000 股。Dimensional Fund Advisors LP 在第三季度购买了 Avalo Therapeutics 的新股份，价值约 $143,000。Boothbay Fund Management LLC 在第二季度购买了 Avalo Therapeutics 的新股份，价值约 $56,000。最后，AlphaCentric Advisors LLC 在第一季度购买了 Avalo Therapeutics 的新股份，价值约 $174,000。目前 87.06% 的股票由机构投资者持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员买卖</h2>
</div><p>In related news, insider Paul Varki sold 75,063 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the sale, the insider directly owned 3,634 shares in the company, valued at $73,297.78. This represents a 95.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $18.01, for a total value of $71,499.70. Following the sale, the insider owned 3,622 shares in the company, valued at approximately $65,232.22. This trade represents a 52.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 138,078 shares of company stock worth $2,501,346 in the last three months. Insiders own 4.46% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Paul Varki 于 5 月 6 日星期三出售了 75,063 股该股票。该股票的平均售价为 $20.17，总交易额为 $1,514,020.71。出售后，内部人士直接持有该公司 3,634 股，价值 $73,297.78。这代表其持股比例减少了 95.38%。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，内部人士 Mittie Doyle 于 4 月 6 日星期一出售了 3,970 股该股票。该股票的平均售价为 $18.01，总价值为 $71,499.70。出售后，内部人士持有该公司 3,622 股，价值约 $65,232.22。此交易代表其持股比例减少了 52.29%。有关此交易的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。内部人士在过去三个月内共出售了价值 $2,501,346 的 138,078 股公司股票。内部人士持有该公司 4.46% 的股票。</p>
</div><h2>Avalo Therapeutics News Roundup</h2>
<div class="lb-trans"><h2>Avalo Therapeutics 新闻汇总</h2>
</div><p>Here are the key news stories impacting Avalo Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Avalo Therapeutics 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright kept a Buy rating on Avalo Therapeutics and reiterated a $35 price target, signaling confidence in the company’s longer-term upside.</li>
<li>Positive Sentiment: The firm raised its earnings estimates for several periods, including FY2026 to ($2.02) per share and FY2027 to ($1.78) per share, suggesting improving expectations versus prior forecasts.</li>
<li>Positive Sentiment: HC Wainwright also significantly improved its Q4 2026, Q3 2026, and Q2 2026 EPS estimates, which can be read as a more constructive view on Avalo’s outlook.</li>
<li>Neutral Sentiment: The updates are research-note revisions, not a company announcement, so they may influence sentiment but do not by themselves change Avalo’s fundamentals. AVTX stock page</li>
<li>Negative Sentiment: Despite the upgrades, Avalo is still projected to lose money across the forecast period, with consensus FY2025 earnings at about ($3.00) per share, underscoring ongoing profitability risk.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：HC Wainwright 对 Avalo Therapeutics 维持买入评级，并重申 $35 的目标价，显示出对公司长期上涨潜力的信心。</li>
<li>积极情绪：该公司上调了多个时期的收益预期，包括 2026 财年每股（$2.02）和 2027 财年每股（$1.78），表明对之前预测的期望有所改善。</li>
<li>积极情绪：HC Wainwright 还显著提高了对 2026 年第四季度、第三季度和第二季度的每股收益预期，这可以被解读为对 Avalo 前景的更积极看法。</li>
<li>中性情绪：这些更新是研究报告的修订，而不是公司公告，因此可能会影响情绪，但本身并不会改变 Avalo 的基本面。AVTX 股票页面</li>
<li>消极情绪：尽管进行了升级，Avalo 仍预计在预测期内亏损，2025 财年共识收益约为每股（$3.00），突显了持续盈利的风险。</li>
</ul>
</div><h2>About Avalo Therapeutics</h2>
<div class="lb-trans"><h2>关于 Avalo Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.</p>
<div class="lb-trans"><p>Avalo Therapeutics 是一家临床阶段的生物技术公司，专注于发现、开发和商业化用于心脏代谢、纤维化和炎症疾病的新疗法。该公司的专有药物设计平台能够创造具有优化药代动力学特征的长效前药，旨在提高疗效、安全性和患者依从性。通过利用这一技术，Avalo 旨在解决现有治疗方法未能充分满足的疾病进展的关键驱动因素。</p>
</div><p>Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.</p>
<div class="lb-trans"><p>其主要项目包括 AVTX-002，这是一种首创的前药候选药物，旨在抑制肾素原，用于治疗高血压及相关心血管疾病，以及 AVTX-006，这是一种早期候选药物，针对与纤维化和代谢功能障碍相关的通路。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参见</h2>
</div><ul>
<li>Five stocks we like better than Avalo Therapeutics</li>
<li>Why Trump’s Amazon Stock Sale May Not Matter at All</li>
<li>Why Applied Optoelectronics Stock May Be Near a Turning Point</li>
<li>From High-Yield to High-Growth: 3 Stocks Boosting Dividends</li>
<li>Is Everspin Technologies the Next AI Edge Breakout?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Avalo Therapeutics</li>
<li>为什么特朗普的亚马逊股票出售可能根本无关紧要</li>
<li>为什么应用光电子公司的股票可能接近转折点</li>
<li>从高收益到高增长：三只提升股息的股票</li>
<li>Everspin Technologies 会成为下一个 AI 边缘突破吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZUWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=AVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Avalo Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Avalo Therapeutics 吗？</h2>
</div><p>Before you consider Avalo Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Avalo Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Avalo Therapeutics 并不在名单上。</p>
</div><p>While Avalo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Avalo Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

分析师提高了 Avalo Therapeutics 的第二季度每股收益预测